Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Clinical trial NCT01176474 · COMPLETED
Trial details
- NCT number
- NCT01176474
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-08-13
- Primary completion
- 2020-08-01
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.